Search

everythinglearnresearchcommunity

for

Search:↓

Children with classic congenital adrenal hyperplasia have thicker heart fat and are at higher risk for heart problems and early atherosclerosis.

Children with classic congenital adrenal hyperplasia have thicker heart fat and more heart and blood vessel risk factors, especially if their condition is not well-controlled.

The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.

A new system helps better diagnose and treat female androgenization conditions like PCOS.

Some parents have a mild form of congenital adrenal hyperplasia without symptoms, and they usually don't need treatment.

The document suggests treating individuals with nonclassic congenital adrenal hyperplasia who show symptoms, especially those related to excess male hormones.

Siblings with signs of virilization should be tested for non-classical congenital adrenal hyperplasia, which does not affect adult height but may impact fertility and well-being if untreated.

Women with non-classic congenital adrenal hyperplasia have higher risk for heart and metabolic problems.

Nonclassic congenital adrenal hyperplasia is a common genetic disorder that can cause a range of symptoms and requires personalized treatment.

Ketoconazole can treat ovarian hyperandrogenism but should be used cautiously with monitoring and birth control.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

The patient's high testosterone was reduced by a medication that suppresses gonadotropin.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

The conclusion is that young women with excessive hair growth should be quickly tested for hormonal issues and treated to improve their social well-being.

A woman's severe male hormone excess was caused by a small, hard-to-find ovarian tumor.

Women with hair loss had higher levels of certain hormones, suggesting a link to a condition like PCOS.

Most women with excess hair growth have an underlying hormonal issue, often treated with medication and hair removal methods.

PCOS starts in adolescence with hormonal issues, leading to adult health problems, and early treatment is crucial.

Hormonal treatments can help with acne but are not the first choice due to side effects and the need for careful patient selection.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

The conclusion is that removing both ovaries is the best treatment for excess male hormones in postmenopausal women, with medication as another option, and managing insulin resistance is important for diagnosis and treatment.

Effective hirsutism management requires identifying the cause, combining new and traditional treatments, and setting realistic expectations for patients.

Excessive body hair in women can be caused by various conditions and treated with medication like Diane® 35 or androgen blockers.

GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.

Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.

PCOS affects about 4% of women in the southeastern U.S. equally across Black and White populations.

The document concludes that accurate diagnosis and personalized treatment are important for skin problems in women with PCOS.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Androgens play a complex role in skin conditions like acne and hair loss in women, and normal blood levels don't always show true androgen status.

About 3% of high school girls aged 14-18 in Isfahan, Iran, have polycystic ovary syndrome.